University of Aberdeen, Rowett Institute
Aberdeen, AB25 2ZD, United Kingdom
NCT Number: NCT06714552
Diabetes and cardiovascular disease account for millions of deaths per year. One of the risk factors for both conditions is high blood sugar, particularly after eating (postprandial hyperglycaemia). Lowering blood sugar levels after a meal is expected to have a positive effect on preventing metabolic and cardiovascular diseases and improving the metabolic control of those who already suffer from these conditions.
The aim of this study is to investigate the effect of Oligomate® (beta-galacto-oligosaccharide) on postprandial glycaemia when used as a partial replacement of glycaemic carbohydrates in a beverage in otherwise healthy volunteers. Volunteers will be given water with either Oligomate® or glucose (control) added. Blood samples will be collected at eight time points (two before drinking the beverage and six after) to measure glucose and insulin levels.
This study is active but is not currently recruiting participants.
18 year–65 year
All sexes
Interventional
Not applicable
Aberdeen, AB25 2ZD, United Kingdom
A single-centre, single-blind, randomised, controlled, cross-over, acute feeding trial will be conducted. The recruitment and study visits will be carried out at the Human Intervention Studies Unit (HISU) of the Rowett Institute.
A recruitment visit will be scheduled to screen for eligibility. During the visit, informed consent will be obtained before volunteers complete a health questionnaire, have their height and weight measured, and their veins checked to assess suitability for blood sample collection. A finger prick blood sample will then be taken to measure HbA1c levels. If a volunteer is eligible, the first study visit will be scheduled and they will be asked to fast for 12 hours the night before. A frozen high carbohydrate vegetarian ready-meal will be provided, which they will consume at home the evening before the study visit and before the fasting period.
During the study visits, the postprandial glycaemic response will be measured immediately after consumption of the supplement or control on two occasions separated by a wash-out period of 7-14 days. Briefly, subjects will arrive in the morning after having consumed the high carbohydrate meal the night before, followed by a 12 hr overnight fast. After recording body weight, a cannula will be inserted into an antecubital vein of one arm by a trained cannulist to allow repeated blood sampling during the assessment (approx. 6 ml collected per sample time to a total of 48 ml per visit). After obtaining two initial fasting blood samples (at -10min and -5min), subjects will consume the test beverage within 5 min. Further blood samples will be obtained at 15, 30, 45, 60, 90 and 120 min after ingestion to complete the postprandial glycaemic response assessment.
At the end of the first visit volunteers will receive the second ready-meal, identical to the first, which they will be asked to consume the evening before the second study visit, before the fasting period commences. During the second study visit, participants will consume the same beverage with the alternate supplement and complete the opposite arm of the postprandial glycaemic response assessment.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
24.0 g Oligomate® in 100 mL water
17.8 g glucose in 100 mL water
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. iAUC will be calculated using the trapezoidal rule with the baseline value of fasting plasma glucose subtracted.
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. tAUC will be calculated using the trapezoidal rule with zero as the baseline.
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. The peak plasma glucose concentrations for each arm will be compared.
Time frame: 10 and 5 min before beverage consumption, 15, 30, 45, 60, 90, 120 min after beverage consumption
Plasma glucose levels obtained from blood samples collected before and after beverage consumption will be determined using an automated clinical analyser. iCMax will be calculated using fasting plasma glucose levels as baseline.
Time frame: baseline, 30, 60, 120 min after beverage consumption
Plasma insulin levels will be determined using ELISA from blood samples obtained, at several time points.
iAUC will be calculated using the trapezoidal rule with baseline value of fasting plasma insulin subtracted.
Time frame: baseline, 30, 60, 120 min after beverage consumption
Plasma insulin levels will be determined using ELISA from blood samples obtained at several time points. tAUC will be calculated using the trapezoidal rule with zero as the baseline.
Time frame: baseline, 30, 60, 120 min after beverage consumption
Plasma insulin will be determined using ELISA from blood samples obtained at several time points. Peak plasma insulin levels for each arm will be compared.
University of Aberdeen
Other
Effect of the Replacement of Glycaemic Carbohydrates With Galacto-Oligosaccharide (GOS) Supplementation on Postprandial Glycaemic Response in Healthy Adults
Acronym: SURE-BloG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06640335
Glucose Metabolism Disorders, Hyperglycemia
Singapore
View Trial DetailsNCT07688694
Diabetes Mellitus, Diabetes Mellitus, Type 2
Mysore, Karnataka, India
View Trial DetailsNCT03836495
Energy Expenditure, Glucose Metabolism Disorders
Beirut, Lebanon
View Trial DetailsNCT04430439
Behavior, Behavioral Symptoms
Irvine, California, United States
View Trial Details